Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588144 | 0.89 | KDM4E (0.46) | KDM4ETSHRALDH1A1CYP3A4 | |
| SCHEMBL15641127 | 0.86 | KDM4E (0.44) | KDM4ETSHRALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL8391514 | 0.86 | KDM4E (0.44) | KDM4ETSHRALDH1A1CYP3A4 | |
| SCHEMBL12575017 | 0.86 | ANPEP (0.44) | ANPEPKDM4ETSHRADH1BADH1C | |
| SCHEMBL3181743 | 0.84 | TSHR (0.45) | KDM4ETSHRCYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL21661075 | 0.82 | ANPEP (0.39) | ANPEPKDM4ETSHRADH1BADH1C | |
| SCHEMBL15641247 | 0.82 | TSHR (0.43) | KDM4ETSHRCYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL18756500 | 0.81 | ANPEP (0.35) | ANPEPKDM4ETSHRADH1BADH1C | |
| SCHEMBL2431058 | 0.80 | KDM4E (0.37) | ANPEPKDM4ETSHR | |
| SCHEMBL4935953 | 0.79 | LMNA (0.40) | ANPEPKDM4ETSHRADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| WO-2003019383-A1 | CRYSTALLINE ALUMINOPHOSPHATE PRODUCTION PROCESS AND CRYSTALLINE ALUMINOPHOSPHATE | SHOWA DENKO KK (JP) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | NDUFAB1, ATG7, HADHA | ANPEP 3045/4885KDM4E 3678/4885TSHR 3249/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | ANPEP 419/4885KDM4E 107/4885TSHR 2866/4885 |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | ANPEP 2744/4885KDM4E 4665/4885TSHR 3891/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | ANPEP 419/4885KDM4E 107/4885TSHR 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.